MX2020004894A - Composiciones que comprenden un inhibidor de demetilasa-1 especifico de lisina. - Google Patents
Composiciones que comprenden un inhibidor de demetilasa-1 especifico de lisina.Info
- Publication number
- MX2020004894A MX2020004894A MX2020004894A MX2020004894A MX2020004894A MX 2020004894 A MX2020004894 A MX 2020004894A MX 2020004894 A MX2020004894 A MX 2020004894A MX 2020004894 A MX2020004894 A MX 2020004894A MX 2020004894 A MX2020004894 A MX 2020004894A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- specific demethylase
- lysine specific
- compositions
- lysine
- Prior art date
Links
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title abstract 5
- 239000004472 Lysine Substances 0.000 title abstract 5
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 1
- NBAIXBAUHIQQGF-UHFFFAOYSA-N NC1CCN(CC1)C=1N(C(C(=C(N1)C1=CC(=C(C#N)C=C1)F)C1=CC(=C(C=C1)OC)F)=O)C Chemical compound NC1CCN(CC1)C=1N(C(C(=C(N1)C1=CC(=C(C#N)C=C1)F)C1=CC(=C(C=C1)OC)F)=O)C NBAIXBAUHIQQGF-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describen en la presente formas amorfas y cristalinas de sales farmacéuticamente aceptables del inhibidor de demetilasa-1 específico de lisina, 4-(2-(4-amino-piperidin-1-il)-5-(3-fluoro-4- metoxi-fenil)-1-metil-6-oxo-1, 6-dihidro-pirimidin-4-il)-2-fluorob enzonitrilo. También se describen composiciones farmacéuticas adecuadas para administración a un mamífero que incluye el inhibidor de demetilasa-1 específico de lisina, y métodos para utilizar el inhibidor de demetilasa-1 específico de lisina para tratar enfermedades o condiciones que están asociadas con la actividad de demetilasa-1 específica de lisina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562251507P | 2015-11-05 | 2015-11-05 | |
| PCT/US2016/060694 WO2017079670A1 (en) | 2015-11-05 | 2016-11-04 | Compositions comprising an inhibitor of lysine specific demethylase-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020004894A true MX2020004894A (es) | 2021-11-03 |
| MX387607B MX387607B (es) | 2025-03-18 |
Family
ID=58662888
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018005620A MX373363B (es) | 2015-11-05 | 2016-11-04 | Composiciones que comprenden un inhibidor de demetilasa-1 específico de lisina. |
| MX2020004894A MX387607B (es) | 2015-11-05 | 2016-11-04 | Composiciones que comprenden un inhibidor de demetilasa-1 especifico de lisina |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018005620A MX373363B (es) | 2015-11-05 | 2016-11-04 | Composiciones que comprenden un inhibidor de demetilasa-1 específico de lisina. |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US9828358B2 (es) |
| EP (1) | EP3371152B1 (es) |
| JP (1) | JP6995043B2 (es) |
| CN (1) | CN108473442B (es) |
| AR (1) | AR106612A1 (es) |
| AU (1) | AU2016349707B2 (es) |
| CA (1) | CA3004300C (es) |
| CY (1) | CY1124078T1 (es) |
| DK (1) | DK3371152T3 (es) |
| ES (1) | ES2846951T3 (es) |
| HR (1) | HRP20210144T8 (es) |
| HU (1) | HUE053449T2 (es) |
| LT (1) | LT3371152T (es) |
| MX (2) | MX373363B (es) |
| PL (1) | PL3371152T3 (es) |
| PT (1) | PT3371152T (es) |
| RS (1) | RS61404B1 (es) |
| SI (1) | SI3371152T1 (es) |
| SM (1) | SMT202100044T1 (es) |
| TW (1) | TW201720808A (es) |
| WO (1) | WO2017079670A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3137169T1 (sl) | 2014-05-01 | 2022-04-29 | Celgene Quanticel Research, Inc. | Inhibitorji lizin specifične demetilaze-1 |
| PT3371152T (pt) | 2015-11-05 | 2021-02-01 | Celgene Quanticel Res Inc | Composições compreendendo um inibidor de lisina específica desmetilase-1 com um anel de pirimidina e sua utilização no tratamento do cancro |
| WO2018083189A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| MA51507A (fr) | 2016-12-09 | 2020-11-11 | Constellation Pharmaceuticals Inc | Marqueurs pour un traitement personnalisé du cancer avec des inhibiteurs de lsd1 |
| LT3661510T (lt) | 2017-08-03 | 2025-01-27 | Oryzon Genomics, S.A. | Elgesio pakitimų gydymo būdai |
| SG11202109159VA (en) | 2019-03-20 | 2021-10-28 | Oryzon Genomics Sa | Methods of treating borderline personality disorder |
| CN120837494A (zh) | 2019-03-20 | 2025-10-28 | 奥莱松基因组股份有限公司 | 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法 |
| MX2021015447A (es) * | 2019-06-13 | 2022-04-06 | Celgene Corp | Métodos de tratamiento del cáncer dirigidos a tumores fríos. |
| US20220249528A1 (en) | 2019-06-20 | 2022-08-11 | Celgene Corporation | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
| WO2021004610A1 (en) | 2019-07-05 | 2021-01-14 | Oryzon Genomics, S.A. | Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors |
| CN116056707A (zh) * | 2020-06-05 | 2023-05-02 | 赛尔基因昆蒂赛尔研究公司 | 治疗前列腺癌的方法 |
| ES2919083R1 (es) * | 2020-06-29 | 2022-07-26 | Celgene Quanticel Res Inc | Métodos de tratamiento de cáncer de próstata |
| KR20230167102A (ko) | 2021-04-08 | 2023-12-07 | 오리존 지노믹스 에스.에이. | 골수성 암 치료를 위한 lsd1 억제제의 조합물 |
| JP2025516648A (ja) | 2022-05-09 | 2025-05-30 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｌｓｄ１阻害薬を用いるｎｆ１変異腫瘍の治療法 |
| WO2023217758A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| WO2024110649A1 (en) | 2022-11-24 | 2024-05-30 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| WO2003084937A2 (en) | 2002-04-10 | 2003-10-16 | Orchid Chemicals & Pharmaceuticals Limited | Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases |
| CA2513414A1 (en) * | 2002-04-10 | 2003-10-16 | Orchid Chemicals & Pharmaceuticals Limited | Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases |
| US20070270446A1 (en) * | 2004-10-06 | 2007-11-22 | Smithkline Beecham Corporation | Reversed Pyrimidinone Compounds as Calcilytics |
| WO2010038081A2 (en) | 2008-10-03 | 2010-04-08 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
| EP3094627B1 (en) * | 2014-01-17 | 2018-08-22 | Novartis AG | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
| SI3137169T1 (sl) * | 2014-05-01 | 2022-04-29 | Celgene Quanticel Research, Inc. | Inhibitorji lizin specifične demetilaze-1 |
| PT3371152T (pt) * | 2015-11-05 | 2021-02-01 | Celgene Quanticel Res Inc | Composições compreendendo um inibidor de lisina específica desmetilase-1 com um anel de pirimidina e sua utilização no tratamento do cancro |
-
2016
- 2016-11-04 PT PT168631117T patent/PT3371152T/pt unknown
- 2016-11-04 CA CA3004300A patent/CA3004300C/en active Active
- 2016-11-04 LT LTEP16863111.7T patent/LT3371152T/lt unknown
- 2016-11-04 US US15/344,426 patent/US9828358B2/en active Active
- 2016-11-04 AU AU2016349707A patent/AU2016349707B2/en not_active Ceased
- 2016-11-04 SM SM20210044T patent/SMT202100044T1/it unknown
- 2016-11-04 MX MX2018005620A patent/MX373363B/es active IP Right Grant
- 2016-11-04 CN CN201680076854.5A patent/CN108473442B/zh active Active
- 2016-11-04 RS RS20210094A patent/RS61404B1/sr unknown
- 2016-11-04 HR HRP20210144TT patent/HRP20210144T8/hr unknown
- 2016-11-04 MX MX2020004894A patent/MX387607B/es unknown
- 2016-11-04 WO PCT/US2016/060694 patent/WO2017079670A1/en not_active Ceased
- 2016-11-04 DK DK16863111.7T patent/DK3371152T3/da active
- 2016-11-04 ES ES16863111T patent/ES2846951T3/es active Active
- 2016-11-04 HU HUE16863111A patent/HUE053449T2/hu unknown
- 2016-11-04 PL PL16863111T patent/PL3371152T3/pl unknown
- 2016-11-04 SI SI201631055T patent/SI3371152T1/sl unknown
- 2016-11-04 JP JP2018522953A patent/JP6995043B2/ja active Active
- 2016-11-04 EP EP16863111.7A patent/EP3371152B1/en active Active
- 2016-11-07 AR ARP160103391A patent/AR106612A1/es unknown
- 2016-11-07 TW TW105136105A patent/TW201720808A/zh unknown
-
2017
- 2017-10-25 US US15/793,512 patent/US10047069B2/en active Active
-
2018
- 2018-07-10 US US16/032,002 patent/US10316016B2/en active Active
-
2019
- 2019-06-10 US US16/436,541 patent/US10703739B2/en active Active
-
2021
- 2021-01-28 CY CY20211100072T patent/CY1124078T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020004894A (es) | Composiciones que comprenden un inhibidor de demetilasa-1 especifico de lisina. | |
| ZA201800022B (en) | Substituted heterocyclyl derivatives as cdk inhibitors | |
| JOP20200011A1 (ar) | مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp | |
| PH12017500583B1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| WO2016044556A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
| PH12016501457B1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| MX2015012850A (es) | Inhibidores de la arginina metiltransferasa y usos de los mismos. | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| MX385332B (es) | Moduladores de ror-gamma. | |
| JOP20160092B1 (ar) | علاج البيتا ثلاسيميا باستخدام مصطبة لجائنية | |
| WO2014179564A8 (en) | Thiazolopyrrolidine inhibitors of ror-gamma | |
| PH12016502005B1 (en) | Compounds and compositions for inducing chondrogenesis | |
| MX2016011105A (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos. | |
| EA201791021A1 (ru) | 1-[2-(АМИНОМЕТИЛ)БЕНЗИЛ]-2-ТИОКСО-1,2,3,5-ТЕТРАГИДРО-4H-ПИРРОЛО[3,2-d]ПИРИМИДИН-4-ОНЫ КАК ИНГИБИТОРЫ МИЕЛОПЕРОКСИДАЗЫ | |
| PH12017500089A1 (en) | Aldosterone synthase inhibitors | |
| MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| MX2017001869A (es) | Formas cristalinas de un modulador de receptor de estrogeno. | |
| TW201613600A (en) | Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically | |
| UA102355U (ru) | Способ лечения рецидивирующей формы фибрилляции предсердий у больных с ишемической болезнью сердца | |
| MX2016010919A (es) | 4-bencilsulfonil-2-butenonitrilo. | |
| IN2014DE00822A (es) |